In vivo imaging resolves tumor cell fractions in glioma, suggesting improved monitoring and assessment.
Motivation: Monitoring of tumor progression and therapeutic efficacy will benefit from in vivo imaging technologies that can estimate cancer-cell-specific fractions at the tissue level. Goal(s): To continue developing an MRSI-based method to resolve tumor-cell-specific components within individual imaging voxels. Approach: We combined glioma-cell-specific metabolite profiles at different states and high-resolution MRSI data to resolve glioma cell fractions, validated using GFP-labeled glioma mice. Results: In vivo, in vitro, and ex vivo results demonstrated the effectiveness of our method in resolving tumor cell distribution and monitoring tumor progression. Impact: The proposed approach can assess cell-specific tissue responses, with significant potentials for tumor staging, treatment assessment, and recurrence detections.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: